The spillover effect of the CIIE drives Sanofi's China business to accelerate and deepen its localization layout
楚一帆
发表于 昨天 20:49
116
0
0
As the largest healthcare company in France, Sanofi has participated in the China International Import Expo for the seventh consecutive year. Benefiting from the spillover effect of the CIIE, Sanofi showcased its global R&D pipeline, which includes 12 potential heavyweight products, as well as 7 innovative achievements in the field of immunology at this year's CIIE. In addition, Sanofi announced further promotion of localization, reached a strategic cooperation with Shangyao Holdings, and signed a series of contracts.
Sanofi CEO Paul Hudson said that the CIIE provides an important platform for Sanofi, which not only promotes further opening up of the Chinese market, but also creates more opportunities for potential cooperation between various fields around the world. Sanofi aims to transform the medical model and deeply understands the scale and speed of innovation in China. We look forward to supporting the development of China's world-class medical ecosystem and benefiting patients worldwide.
Sanofi's star product in the field of immune inflammation, Dabitou& reg; He is one of the witnesses and witnesses of 'China's speed'. In September of this year, Dabitou& reg; The new indication for chronic obstructive pulmonary disease has been approved in China, and it is reported that this approval was granted before the approval of the US FDA. Compared to the European Union and the United States, China has the shortest approval time, once again breaking the record for innovative drugs benefiting Chinese patients. Its other product, Saiyining& reg; In 2021, we will participate in the CIIE and embark on our journey in China. In just one year, we will achieve a "three-level leap" from approval, listing to inclusion in medical insurance at the "Chinese speed" in 2023.
Sanofi Greater China President Shi Wang stated that in the past seven years, thanks to the strong "spillover effect" of the CIIE, Sanofi's business development in China has indeed accelerated. We have also witnessed the Chinese government's firm commitment to promoting pharmaceutical innovation and health through the CIIE. This year, we will once again attend the meeting with multiple innovative achievements in the field of immunology that are "first" or "only" in China and globally, and further deepen cooperation and dialogue with local partners. The Chinese market is crucial to Sanofi, and we always focus on the unmet medical needs of patients, continuously strengthen investment in scientific innovation, business model innovation, and actively build a Chinese pharmaceutical and health innovation ecosystem, and help promote the high-quality development of the industry
During the CIIE, Sanofi announced a strategic partnership with Shangyao Holdings. Based on the good cooperation foundation in the past, both parties will expand their cooperation in the pharmaceutical business field, optimize cooperation models, improve operational efficiency, focus on key products, enhance market accessibility, and promote higher-level industrial chain innovation and cross integration. This is one of the largest, most extensive, and deepest strategic partnerships between the pharmaceutical industry and industry, marking a new step for Sanofi and Shangyao Holdings in promoting collaborative innovation and development in the pharmaceutical industry.
During the CIIE, Sanofi held multiple important signing ceremonies and events at its booth, continuously exploring and practicing localization, increasing investment and layout in the Chinese market. It also signed a memorandum of cooperation with Kaihui Fund to help develop China's pharmaceutical innovation ecosystem, achieve technological breakthroughs and commercial success, and unleash the global potential of Chinese innovation; Signed a strategic cooperation agreement with Tianjing Biotechnology regarding the development, production, and commercialization of the CD73 antibody uliledlimab in Greater China.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Guozheng International: Yum! Brands China is resilient enough to weather the cycle
- General Motors China President: The unique innovation in the Chinese market brings many excellent opportunities
- Ericsson China President Fang Ying: CIIE provides a shared innovation platform for global enterprises
- The Nasdaq China Golden Dragon Index closed down 1.83%, with most popular Chinese concept stocks falling
- Jin Fangqian, Global Vice President of Gilead Sciences: Continue to increase investment in China and bring Chinese innovative drugs to the world
- Merck Life Sciences Vice President Wu Bo: Strengthening localization construction is an important way to address industry challenges
- Abbott brings multiple specialty foods to participate in the 7th CIIE, promoting China's silver economy
- Abbott announces the launch of its new women's health drug Fenyouning in China
- Sony releases' Sony China Sustainable Development Report '
- 2024 Enter the Expo | Improve local innovation ability, Nike digs gold in China's running market
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
自動車企業のStellantisグループは現地時間11月6日、米オハイオ州トレドのJeep工場で過剰在庫を消化するために約1100人を削減すると発表した。同社はJeep Gladiatorピックアップを生産するToledo South工場を2班制 ...
- 什么大师特
- 昨天 10:15
- 支持
- 反对
- 回复
- 收藏